Gabriela Osmulska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gabriela Osmulska has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Emilia Kiełczyńska
Student Scientific Organization, Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wrocław, Poland
1 shared publication - Klaudia Kukla
Scientific Society for Neurotoxicology, Department of Forensic Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 4J, 50-345 Wroclaw, Poland
1 shared publication - Krzysztof Gomułka
Clinical Department of Allergology and Internal Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland
1 shared publication - Martyna Kowalczyk
Student Scientific Organization, Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wrocław, Poland
1 shared publication - Michał Terlecki
Student Research Group of Allergology and Internal Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland
1 shared publication - Wiktoria Brzeczek
Student Research Group of Allergology and Internal Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland
1 shared publication
Latest Publications
- Open Access
- 15 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1865
Possible Crosstalk Between Small Intestinal Bacterial Overgrowth (SIBO) and Atopic Manifestations—A Short Overview
Small intestinal bacterial overgrowth (SIBO) is an increasingly recognized condition that influences immune responses. It may be linked to atopic disorders such as bronchial asthma (BA), food allergies (FA), chronic spontaneous urticaria (CSU), and mast cell activation syndrome (MCAS). The aim of our study was to perform a structured literature search to assess the possible correlation between SIBO and the presentation of atopic disorders. The prevalence of SIBO was highest in patients with BA (60–100%) and FA (50–87.5%), followed by MCAS (30.9%) and CSU (27.9%). The diagnosis of SIBO was based on lactulose or glucose breath tests. SIBO exacerbated symptoms of atopic diseases, and treating it within BA and MCAS improved the symptoms, in contrast to CSU. The present evidence suggests a possible crosslink between SIBO and atopic manifestations. Bacterial overgrowth appears to trigger the Th2 immune response via the mucosal pathway and low-grade endotoxemia. These result in the increased synthesis of interleukins involved in allergic reactions (IL-4, IL-5, IL-13). Further studies are essential to confirm the clinical significance of this association. The “gut–allergy axis” may offer new therapeutic options and possibly improve quality of life in patients with atopy.
- 15 February 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1865
Open AccessPossible Crosstalk Between Small Intestinal Bacterial Overgrowth (SIBO) and Atopic Manifestations—A Short Overview
Small intestinal bacterial overgrowth (SIBO) is an increasingly recognized condition that influences immune responses. It may be linked to atopic disorders such as bronchial asthma (BA), food allergies (FA), chronic spontaneous urticaria (CSU), and mast cell activation syndrome (MCAS). The aim of our study was to perform a structured literature search to assess the possible correlation between SIBO and the presentation of atopic disorders. The prevalence of SIBO was highest in patients with BA (60–100%) and FA (50–87.5%), followed by MCAS (30.9%) and CSU (27.9%). The diagnosis of SIBO was based on lactulose or glucose breath tests. SIBO exacerbated symptoms of atopic diseases, and treating it within BA and MCAS improved the symptoms, in contrast to CSU. The present evidence suggests a possible crosslink between SIBO and atopic manifestations. Bacterial overgrowth appears to trigger the Th2 immune response via the mucosal pathway and low-grade endotoxemia. These result in the increased synthesis of interleukins involved in allergic reactions (IL-4, IL-5, IL-13). Further studies are essential to confirm the clinical significance of this association. The “gut–allergy axis” may offer new therapeutic options and possibly improve quality of life in patients with atopy.